Opthea to Attend the Citi 2024 Global Healthcare Conference
Opthea Limited (NASDAQ: OPT), a pioneering biopharmaceutical company focused on developing innovative treatments for serious retinal diseases, is making headlines as it gears up to participate in the prominent Citi 2024 Global Healthcare Conference. The event provides an exceptional platform for Opthea to share its insights and updates with investors.
Key Conference Participation Details
Fred Guerard, PharmD, who serves as the Chief Executive Officer of Opthea, will lead the charge in engaging with investors. He will facilitate one-on-one meetings, offering personalized insights into the company’s trajectory. Additionally, Guerard will take part in a panel discussion aimed at addressing critical issues in ophthalmology, titled "Eyes Wide Open on Ophthalmology." This session is an exciting opportunity to highlight advancements in managing retinal diseases, particularly wet age-related macular degeneration (wet AMD).
Panel and Presentation Information
The conference is scheduled for December 5, 2024, making it a key date for stakeholders interested in the latest developments in the biopharmaceutical sector. Guerard’s presentation is set for 1:45 PM ET, during which he will discuss the company's innovative approaches and future plans.
Innovative Therapies from Opthea
At the heart of Opthea's mission is its lead candidate, sozinibercept. This groundbreaking therapy is designed to meet the crucial needs in treating retinal diseases that are significantly affecting patients' lives. Currently, sozinibercept is undergoing rigorous testing in two pivotal Phase 3 clinical trials known as COAST and ShORe. These trials are essential for determining the therapy's efficacy when used alongside existing anti-VEGF-A treatments, aiming to enhance patient outcomes substantially.
Continuous Progress in Clinical Trials
The ongoing trials have shown promise, indicating that sozinibercept may deliver superior vision improvements compared to current standard treatments for wet AMD and diabetic macular edema (DME). This progress is crucial as it reflects Opthea's commitment to addressing the unmet medical needs of patients facing these debilitating conditions.
Engagement with the Community
Opthea invites everyone interested in their innovative projects to visit their website, where they will provide real-time updates during the conference. Stakeholders can gain insights into the company’s clinical trials, product developments, and their overarching vision for the future of retinal disease treatment.
Investor and Media Inquiries
For those keen to learn more or engage with the company further, Opthea encourages inquiries through their investor relations and media contacts. PJ Kelleher of LifeSci Advisors, LLC, is available for investor-related questions, while Silvana Guerci-Lena from NorthStream Global Partners handles media inquiries. Their dedication to clear communication showcases Opthea's readiness to foster relationships with investors and the public alike.
Frequently Asked Questions
What is Opthea's primary focus?
Opthea primarily focuses on developing innovative therapies for retinal diseases, especially wet age-related macular degeneration and diabetic macular edema.
Who will be presenting at the Citi conference?
Fred Guerard, the CEO of Opthea, will be presenting at the conference and leading discussions with investors.
When is the Citi 2024 Global Healthcare Conference?
The conference is scheduled for December 5, 2024, where Opthea's participation includes investor meetings and a panel discussion.
What is sozinibercept?
Sozinibercept is Opthea's lead product candidate aimed at improving treatment outcomes for retinal diseases through enhanced efficacy when combined with existing therapies.
How can I learn more about Opthea's developments?
Interested individuals can visit Opthea's website and follow its updates on social media platforms for the latest news and developments.
